MarketPulse
A

$ALGS

3 articles found
3 positive
0 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Aligos Scores $25M Upfront in China Deal for Hepatitis B Drug

Aligos Therapeutics licenses pevifoscorvir to Xiamen Amoytop for Greater China development, receiving $25M upfront and up to $420M in milestones.
ALGSclinical developmentpevifoscorvir sodium
GlobeNewswire Inc.GlobeNewswire Inc.··Aligos Therapeutics, Inc.

Aligos Therapeutics Cuts Losses 82% While Advancing Hepatitis B Pipeline

Aligos reports $24.2M net loss in 2025, down 82% YoY. Key hepatitis B study enrollment complete; cash runway extends to Q3 2026.
ALGSPhase 2 clinical trialfinancial results
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Aligos Presents Clinical Advances in Hepatitis B and Coronavirus Inhibitor Programs

Aligos presented clinical progress for hepatitis B and coronavirus treatments at CROI. Pevifoscorvir showed strong viral suppression, while ALG-097558 provided dosing data for impaired patients.
ALGSclinical trialhepatitis B virus (HBV)